Variablea | IPM group | Placebo group |
---|---|---|
Number | 294 | 297 |
Gender, male, n (%) | 225 (77) | 224 (75) |
Age, years, mean ± SD | 10.2 ± 2.8 | 10.5 ± 3.0 |
 Baseline age 5–11, n (%) | 206 (70) | 190 (64) |
 Baseline age 12–15, n (%) | 59 (20) | 72 (24) |
 Baseline age 16–18, n (%) | 29 (10) | 35 (12) |
Weight, kg, mean ± SD | 24.8 ± 8.1 | 26 ± 9.7 |
PCR Plasmodium, n (%) | 16 (5.4) | 18 (6.1) |
 PCR P. falciparum, n (%) | 3 (1.0) | 11 (3.7) |
 PCR P. vivax, n (%) | 13 (4.4) | 7 (2.4) |
Haemoglobin concentration, g/dl, mean ± SD | 12.0 ± 0.8 | 12.0 ± 0.9 |
Haematocrit, mean ± SD | 37.4 ± 3.1 | 37.7 ± 2.5 |
Mean corpuscular volume (MCV), fl, mean ± SD | 74.2 ± 5.5 | 73.7 ± 5.7 |
 MCV < 75 fl, n (%) | 147 (52) | 164 (57) |
 MCV ≥ 75 fl, n (%) | 147 (48) | 132 (43) |
Ferritin concentration, µg/l, median (IQR) | 43.5 (28.3–64.8) | 40.4 (26.6–64.2) |
Number with ferritin < 30 µg/l, n (%) | 77 (26) | 82 (28) |
 With MCV < 75 fl, n (%) | 39 (13) | 52 (18) |
 With MCV ≥ 75 fl, n (%) | 38 (13) | 29 (10) |
Number with ferritin < 12 µg/l, n (%) | 18 (6) | 33 (11) |
 With MCV < 75 fl, n (%) | 6 (2) | 21 (7) |
 With MCV > 75 fl, n (%) | 12 (4) | 11 (4) |
Suspected thalassaemia, n (%)b | 62 (21) | 74 (25) |